water continu swim wide moat
updat forecast estim
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim
price data
rate updat
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
water tool help client perform scientif research provid
analyt instrument servic suppli compani
special liquid chromatographi mass spectrometri
sale use primarili
pharmaceut firm analyz molecul structur
drug discoveri develop product process
tool also use food environment qualiti test
well industri applic addit help
scientist examin physic properti variou materi
thermal analysi tool
throughout use life system sell relat
consum chromatographi column sampl
prepar kit tool half sale
consid recur even instrument sale rel
sticki especi highli regul pharmaceut end
market repres half sale appreci
water concentr highli regul space
signific mani life science/diagnost peer given
healthi growth profil signific switch cost associ
pharmaceut field concentr help
water grow midsingl digit continu gener high
howev growth under-perform expect
recent end-market challeng includ potenti
weak due coronaviru china sale
competit pressur like agil step
lc-m product offer although manag may
mistim product refresh cycl bit recent launch
lc-m tool bioaccord cater specif need
biologic-focus custom help compani regain
foot also although govern initi surround
china food-qual infrastructur gener pharmaceut
price creat near-term challeng believ exposur
china long-term posit
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
offer liquid chromatographi mass spectrometri thermal
analysi tool primarili biopharmaceut
custom analyt instrument provid essenti inform
variou product molecular structur physic properti
help client enhanc health well-b end user
instruments/informat servic consum account
approxim sale respect
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
keep fair valu estim per share
impli price/adjust earn multipl
top line incorpor annual growth
next five year end market expect
growth led pharmaceut overal
growth expect high-single-digit biologic-rel
growth consid robust gener demand trend
water new bioaccord lc-m product low-single-digit
growth small molecul could remain weak
near term given uncertainti around demand china
gener expect
low-single-digit growth annual basi
industri academic/govern market
power end market regul
pharmaceut end market also demand trend
intermedi term eventu may affect weaker
econom environ industri market well
budget constraint academ govern market
expect adjust earn per share rise roughli
compound annual next five year
sale growth primarili share-repurchas activ
retreat slightli base rel weak growth
oper margin assum rise slightli
base-cas scenario also incorpor
manag goal increas net leverag roughli
time near term significantli boost
net interest expens go forward howev rise
net interest expens off-set expect
share repurchas adjust ep basi total
repurchas activ account roughli basi point
annual earn growth rate next
discount assumpt weight averag
cost capit around
give water medium uncertainti rate thank
sticki end market especi pharmaceut
result rel steadi demand trend despit
variabl major end market -- industri
bull-cas scenario result fair valu estim
assum greater-than-anticip uptak firm
new product innovation-rel mix benefit quick
rebound china scenario expect sale growth
compound annual
base-cas scenario oper margin rise
versu base-cas scenario
larg expect share repurchas think adjust ep
grow compound annual next
five year use base-cas earn assumpt
water valu time project earn
bear-cas scenario result fair valu
estim model incorpor roughli
annual top-lin growth oper margin fall
scenario assum increas price
pressur market share loss competit addit
potenti slowdown end market case net
incom actual declin slightli five-year
forecast period adjust ep grow compound
annual scenario due expect share-repurchas
activ near term use base-cas earn
assumpt valu time project earn
bear-cas scenario
instrument busi consist liquid chromatographi
mass spectrometri thermal analysi tool intellectu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
scientist earli project phase must continu
innov abil innov contribut
intang asset busi well
gener
initi choic tool base intang
asset benefit substanti switch cost
end market importantli half water
develop
manufactur pharmaceut sticki
busi contribut wide-moat statu
end market analyt tool critic compon
product method variou drug
specifi directli molecul regulatori approv
applic regul requir product method
throughout drug life-cycle chang
manufactur process includ qualiti assur
qualiti control test typic perform tool
would requir approv regul regulatori
requir reproduc concern employe
train factor creat switch cost water
pharmaceut custom result long
potenti benefit period water regul market
brand small molecul period last
year discoveri patent expir larg
molecul biolog period last even longer
difficult manufactur process also
use product method brand
manufactur reduc product variabl
adopt gener manufactur creat even
longer benefit period water specif molecul
overal concentr highli regul
biopharmaceut end market extend prospect
econom profit long period view
water wide-moat firm compar favor
mani narrow-moat life scienc diagnost
compani typic enjoy less concentr
properti on-going innov creat intang asset
moat sourc regulatori reproduc factor
contribut switch cost end user moat
sourc crucial advantag target
market advantag water enjoy
profit near top life scienc market
oper margin return invest capit roughli
calcul
water offer differenti technolog protect
variou intang asset includ patent copyright
trademark portfolio intellectu properti
innov prowess keep competitor directli copi
technolog sinc even slightli differenti technic
featur caus end user prefer one tool
anoth similar tool precis scientif end
differenti
technolog signific moat sourc differenti
properti tool affect perform
accuraci speed variou project enabl
differenti product featur creat intang asset
inform decis use tool specif applic
particularli begin project remain relev
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
chang firm moat exampl instrument
alreadi specifi manufactur process
biopharmaceut would unlik chang
water competitor benefit unless regulatori
requir pharmaceut look like eas
substanti unlik opinion would
expect moat trend stay stabl given inher
sticki end market particular howev
manag appear open acquisit
past activ significantli alter water
exposur regul market tool requir
much flatter learn curv user view moat
moat trend could chang
see narrow still strong moat around water
other end market materi scienc food
environment applic due less-intens regulatori
pressur intang asset switch cost support
water moat end market well
throughout oper analyt instrument
long use live typic year water
often benefit razor-and-blad busi model
life-cycle half compani revenu
recur consum servic half
gener one-tim sale
instrument
informat price power organ appear
posit overal annual price appreci primarili
consum servic note
price power rise regul end market
correl well view wider moat
pharmaceut applic compar end
market think relat interoper
column competit instrument therefor less
regul market end user sensit
technolog differ price relat product
servic end instrument
life-cycle regul market howev think
reproducibility- training-rel switch cost
present water end market even
highli regul pharmaceut busi
water moat trend appear stabl us intang
asset front compani continu innov improv
perform analyt tool well user
interfac innov help maintain
market share initi project decis made
crucial on-going system placement
continu relev industri also much
water competit advantag associ regulatori
reproducibility-rel switch cost expect littl
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
owat analyt instrument remain gold
standard sever applic especi lc-m
pharmaceut firm regul preserv
consist recur sale mani year
owat remain extrem focus organ
creat potenti cash flow variabl
product fall favor end market face
ohistor maintain disciplin
capital-alloc strategi preserv return
invest capit near top industri
expect continu even acquisit
owat continu benefit expand brand
gener biopharmaceut increas
food safeti environment test variou
ocompetit like agil thermo
fisher among other put consist pressur
water innov
owat increas debt leverag purchas
share fair valu estim may
best use sharehold capit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
end owe billion debt
compar million cash invest
net debt/ebitda posit time expect leverag
continu rise compani aim net
debt/ebitda time tax reform given
easi access cash held oversea compani plan
push signific cash sharehold januari
share-repurchas program compani use
billion author expect
repurchas anoth million share debt
financ move closer net leverag goal
time water pay dividend made
larg acquisit recent year investor know
manag appetit acquisit appear
grown recent would expect tuck-in rather
transform acquisit near futur
help maintain reason leverag
give water medium uncertainti rate thank
sticki end market especi pharmaceut
result rel steadi demand trend despit
variabl major end market -- industri
academic/govern notabl though half
compani sale come system placement
delay even cancel challeng condit
exampl industri client may choos stretch
use exist system rather purchas new
pharmaceut develop project fail end-market
dynam chang saw chines
gener pharmaceut market earli system
purchas may fall even steadi pharmaceut end
market signific constraint govern research
budget could depress spend among academ
econom downturn also
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
govern custom addit remain
technolog compani must innov remain
relev establish competitor new entrant
introduc better product develop stronger relationship
custom compani may lose market share well
abil extract price increas
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
board
repres date owner name posit common share held report holder issuer
capit research manag compani
share
fund
share
fund
benefit continu
maintain exemplari stewardship rate
advanc focu intern invest
opportun help maintain return invest
capit well peer gener
acquisit water richli valu life
likelihood manag refrain larg
influenc
compani manag team appear align
sharehold although prefer direct use
return invest capit compens polici
manag team highlight roic high
prioriti think benefit sharehold
water continu avoid value-destroy capital-alloc
activ compens compani top manag
team also appear align sharehold
variabl compens structur heavili weight
incent base revenu adjust
recent chang manag financi strategi
creat uncertainti around stewardship go
forward though execut turnov
last year chri connel former
presid restor therapi group
replac dougla berthiaum ceo oconnel
also replac berthiaum chairman board
sherri buck becam cfo previou financi
execut experi libbey
new manag increas access cash
tax reform compani financi strategi chang
somewhat exampl compani increas
financi leverag repurchas share recogn
abl access debt market
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
histor low interest rate question valuat
compani like pay share
remain fair valu estim also increas
net leverag net cash posit may make water
suscept downturn demand product
particularli one-tim system sale repres
half revenu chang add uncertainti
stewardship stori otherwis
strong histor
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
water give weak outlook share remain
water releas fourth-quart result beat capit iq
ep consensu manag gave outlook
well expect plan tweak
near-term estim base result trend
expect significantli chang fair
valu estim suggest share remain overvalu
posit continu view top-tier posit
analyt instrument sticki pharmaceut
end market key contributor wide moat
sustain busi appear
strong growth small-molecul market china
fade fourth quarter sale grew
constant currenc largest widest-moat end market
pharmaceut flat quarter manag
small-molecul
custom end market also contribut declin
china sale quarter industri end
market also declin period food market
strength off-set materi character weak
encourag academ government market
growth manag attribut uptak
new technolog pharmaceut biomed
market contribut lower-than-expect outlook
easi compar period water expect
constant-curr sale growth lower
mid-single-digit growth expect
oper margin around on-going debt-fund
share repurchas compani expect
earn per share growth
significantli expect low-double-digit ep
growth updat model expect balanc
weak trend firm stronger-than-anticip
cash flow gener strong cash flow convers
continu valuat chang materi
wide-moat water releas third-quart result met
capit iq earn per share consensu meet
sale expect given weak demand trend
firm reduc outlook third time year
despit signific share repurchas activ
trim near-term project slightli
enough chang fair valu estim
remain recent trade
quarter grew constant currenc
million sale consensu million
manag previou guidanc
constant currenc growth largest widest-
moat end market pharmaceut led way
constant currenc growth although segment
weaker expect manag highlight
substanti end quarter inconsist
capit purchas small molecul custom
growth end market develop larg
expect industri end market improv
second quarter declin flat year year
compani academ government end market
constant currenc declin weaken sequenti
continu pressur chines food market
weak demand trend caus water reduc
outlook sale earn per share
specif expect constant-curr sale
growth third time year includ
previous origin also expect
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
earn per share growth
third time year includ
previous origin gener
on-going declin expect disappoint
qualiti ep growth remain weak given depend
share repurchas
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
